Drug intelligence / Profile preview

NIDB-3601

Development stage: Unknown
Lead developer: discoveric bio group
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NIDB-3601 is a bispecific antibody currently in the discovery phase for the treatment of neuroinflammation. Developed by Discoveric Bio Beta, the candidate utilizes the κλ body (kappa-lambda body) platform, a proprietary bispecific antibody format that maintains the structure of a standard human IgG while incorporating two different light chains (one kappa and one lambda) to enable dual-targeting. While the specific biological targets remain undisclosed, the program aims to modulate inflammatory pathways within the central nervous system to address neuroinflammatory conditions.

Beyond the preview

Go deeper on NIDB-3601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIDB-3601.

Explore the full profile